Craig Erickson, MD is Professor and psychiatrist at the Cincinnati Children’s Hospital Medical Center, University of Cincinnati College of Medicine- Affiliated. He brings 15 years of experience in clinical trials in the field of neurodevelopmental disorders (NDDs), including autism spectrum disorders (ASD). He is also the principal investigator of STALICLA’s STP1 trial. In this interview, he explains how advances in molecular genetics and the biological understanding of ASD are opening new possibilities for personalized medicine that could, for the first time, help to address its core symptoms and improve the lives of people with autism.
How is ASD treated today in the US and what is the challenge, if any, with this approach?